NCT07704970 QLESP Block for Pain Control in Robotic Partial Nephrectomy
| NCT ID | NCT07704970 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huazhong University of Science and Technology |
| Condition | Renal Cell Carcinoma (Kidney Cancer) |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-09-22 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-09-22 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if an ultrasound-guided nerve block called QLESP works to reduce pain and the need for strong pain medicines after robotic kidney surgery in adults. The main questions it aims to answer are: 1. Does QLESP reduce the total amount of opioid pain medicine participants need in the first 48 hours after surgery? 2. Does QLESP lower pain scores and improve recovery quality after surgery? Researchers will compare participants who receive QLESP block to participants who receive the same numbing medicine injected only at the surgical wound sites. Participants will: 1. Be randomly assigned to receive either QLESP or local wound injection before surgery. 2. Have a patient-controlled pain pump for 48 hours after surgery. 3. Complete pain scores and recovery quality questionnaires at 2, 6, 12, 24, 48, and 72 hours after surgery. 4. Be followed until hospital discharge.
Eligibility Criteria
Inclusion Criteria: * Aged 18 to 75 years * Scheduled for elective robot-assisted partial nephrectomy (RAPN) * American Society of Anesthesiologists (ASA) physical status I to III * Body mass index (BMI) 18 to 35 kg/m² * Voluntarily signed informed consent form Able to understand pain scoring and use of patient-controlled analgesia (PCA) Exclusion Criteria: * Language, communication, or comprehension barriers * Infection at the intended puncture site * Coagulopathy or bleeding diathesis * Known allergy or contraindication to local anesthetics or opioids * Use of analgesic medications within the past 3 months * Peripheral neuropathy * Severe cardiac, hepatic, or renal dysfunction * Pregnancy or breastfeeding * Refusal to participate in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07704970 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Renal Cell Carcinoma (Kidney Cancer). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07704970 currently recruiting?
Yes, NCT07704970 is actively recruiting participants. Contact the research team at wu2018whuh@163.com for enrollment information.
Where is the NCT07704970 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07704970 clinical trial?
NCT07704970 is sponsored by Huazhong University of Science and Technology. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.